文献速递肿瘤 PET/CT

弥漫大B细胞淋巴瘤治疗终点FDG-PET/CT预后价值:视觉Deauville标准与病灶-肝脏SUVmax比值评估系统的比较

The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-15

LLR最佳截断值为1.83,基于LLR的标准在预测疾病进展和死亡事件上特异性、阳性预测值和准确性均高于5PS;LLR阳性是PFS和OS的不良预后因素,且仅LLR≥1.83阳性患者从额外治疗中获得OS获益。

要点

  • LLR最佳截断值1.83,其预测进展/死亡的特异性、阳性预测值和准确性高于Deauville标准。
  • LLR阳性是PFS和OS的独立不良预后因素(多因素分析均p<0.001)。
  • 仅LLR≥1.83的EoT-PET阳性患者从额外治疗中获得OS获益(p<0.05)。

核心结论

  • LLR最佳截断值可能优于Deauville标准,能识别一线免疫化疗后EoT-PET阴性低危DLBCL患者并避免额外治疗的费用和毒性。

研究设计与样本

  • EoT-PET分别用视觉Deauville 5PS和LLR(病灶与肝脏SUVmax比值)评估,LLR截断值由ROC曲线分析获得。
  • 采用Kaplan-Meier生存分析比较患者结局,多因素Cox回归评估预后因素。

主要发现

  • Deauville评分4分患者PFS和OS均显著长于5分患者(均p<0.001),PFS显著短于1-3分患者(p<0.01),OS相似(p=0.057)。
  • 无论阳性定义为DS 4-5还是DS 5,EoT-PET阳性与阴性组间PFS和OS差异均显著(均p<0.001)。
  • LLR最佳截断值为1.83,按此定义阳性和阴性患者间PFS和OS差异均显著(均p<0.001)。
  • 基于LLR的标准在预测疾病进展和死亡事件上特异性、阳性预测值和准确性均高于基于5PS的标准。
  • 多因素分析中,LLR定义的EoT-PET阳性与不良PFS和OS相关(均p<0.001)。

关键数值与推荐

  • LLR最佳截断值为1.83。
  • Deauville 5PS阳性定义分别为DS 4-5或DS 5时,阳性与阴性组间PFS和OS差异均显著(均p<0.001)。
  • LLR≥1.83定义的EoT-PET阳性与阴性患者间PFS和OS差异均显著(均p<0.001)。

临床怎么用

  • 治疗终点FDG-PET/CT评估DLBCL时,可考虑采用LLR(截断值1.83)辅助Deauville标准识别低危阴性患者。
  • LLR≥1.83的EoT-PET阳性患者可能从额外治疗中获得OS获益,而LLR阴性患者额外治疗未显示结局相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to determine a better criterion for end-of-treatment PET (EoT-PET) assessment and prognostic evaluation of patients with diffuse large B cell lymphoma (DLBCL). METHOD: EoT-PET scans were assessed using the visual Deauville 5-point scale (5PS) and LLR, the maximum standard uptake value ratio between the lesion and the liver. The cutoff value of LLR was obtained by receiver operator characteristic curve analysis. Patient outcomes were compared using Kaplan-Meier survival analysis. Prognostic indexes of different criteria were compared. Multivariate Cox regression analysis was performed to evaluate the prognostic factors. RESULTS: Four hundred forty-nine newly diagnosed DLBCL patients who received rituximab-based immunochemotherapy were included, and the median follow-up duration was 41.4 months. Patients with Deauville score (DS) 4 displayed significantly longer PFS and OS compared with patients with DS 5 (both p < 0.001), and they had significantly shorter PFS (p < 0.01) but similar OS (p = 0.057) compared with patients with DS 1-3. The differences in PFS and OS between groups were all significant whether positive EoT-PET was defined as DS 4-5 or DS 5 (all p < 0.001). The optimal cutoff of LLR was 1.83, and both PFS and OS were significantly different between EoT-PET-positive and EoT-PET-negative patients as defined by the cutoff (both p < 0.001). LLR-based criterion displayed higher specificity, positive predictive value, and accuracy than 5PS-based criterion in the prediction of disease progression and death events. In the multivariate analysis, positive EoT-PET (as defined by LLR) was related to unfavorable PFS and OS (both p < 0.001). Additional treatment was not correlated with outcomes of EoT-PET-negative patients either defined by LLR or 5PS or EoT-PET-positive patients classified by 5PS, but it was the only beneficial factor for OS (p < 0.05) in EoT-PET-positive patients with LLR ≥ 1.83. CONCLUSION: The optimal cutoff of LLR may be superior to Deauville criteria in identifying low-risk DLBCL patients with negative EoT-PET after the first-line immunochemotherapy and sparing them the cost and toxicity of additional treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li YH, Zhao YM, Jiang YL, et al. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system. Eur J Nucl Med Mol Imaging. 2021. PMID: 34651231. doi:10.1007/s00259-021-05581-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。